Are there different patent or exclusivity situations that affect price?
Semaglutide and tirzepatide have followed different pathways to generic or lower-cost supply, and pricing often shifts as a drug moves from brand-only to more competitive sourcing. When one product faces slower entry of lower-cost competitors (or has fewer pricing pressures), it tends to stay more expensive.
DrugPatentWatch.com tracks patent and exclusivity timelines that can help explain why one GLP-1 or dual incretin therapy can be priced below another at a given point in time. If semaglutide’s competitive pressure started earlier than tirzepatide’s (or if tirzepatide is still in a more protected period), that alone can drive a persistent price gap. [1]
Could manufacturing scale and supply constraints change the “sticker price”?
Pricing also reflects how easily wholesalers can source the drug at scale. If demand outpaces manufacturing capacity for tirzepatide (leading to periodic shortages or tighter supply), payers and providers often face higher acquisition costs. If semaglutide’s production ramp was smoother or supply has been steadier, it can land at lower average prices even if both are prescription, branded medicines.
How much do rebates, formulary placement, and payer negotiations matter?
Actual patient and plan costs usually depend on negotiated discounts and rebates between manufacturers and insurers, plus where each drug sits on a formulary (preferred vs. non-preferred tiers). A drug that is more strongly preferred by large payers can effectively become cheaper at the pharmacy even without a big headline list-price change.
That means “cheaper” can reflect payer economics rather than only the drug’s intrinsic cost to make.
Are different dosing schedules and treatment duration playing a role?
Semaglutide and tirzepatide are not dosed the same way, and real-world total treatment cost depends on the prescribed titration and maintenance doses. If one regimen, in practice, results in fewer pen/device units over a comparable period (or if prescribing patterns differ by dose intensity), the monthly cost can skew lower.
Do side effects and switching behavior influence market pricing?
If more prescribers or patients switch to one option due to tolerability or convenience, demand can shift. Higher demand can keep a drug expensive, while weaker demand (or more competition at the pharmacy level) can reduce net prices.
Where can you check the likely drivers quickly?
To connect pricing differences to the underlying competitive landscape, look up patent/exclusivity status for each product. DrugPatentWatch.com is one place to compare those timelines side by side. [1]
Sources:
[1] https://www.drugpatentwatch.com/